⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621583 | 0.62 | — | — | |
| SCHEMBL7013288 | 0.57 | — | — | |
| SCHEMBL5822129 | 0.56 | — | — | |
| SCHEMBL298895 | 0.55 | — | — | |
| SCHEMBL8914 | 0.55 | — | — | |
| SCHEMBL7476084 | 0.53 | — | — | |
| SCHEMBL46423 | 0.52 | — | — | |
| SCHEMBL453907 | 0.51 | — | — | |
| SCHEMBL14974556 | 0.50 | — | — | |
| SCHEMBL7384422 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112125914-A | 5-substituted berbamine derivatives, preparation method and application thereof | 杭州卫本药业有限公司 | 2020-12-25 | — | — | CN | claimed |
| US-20150141378-A1 | NITROXYL PROGENITOR COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | claimed |
| US-20240158403-A1 | SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-11932646-B2 | Small molecule myristate inhibitors of Bcr-abl and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112125914-B | 5-substituted berbamine derivatives, preparation method and application thereof | 杭州卫本药业有限公司 | 2024-02-13 | — | — | CN | disclosed |
| EP-3377111-B1 | AMINE PRODRUGS OF PHARMACEUTICAL COMPOUNDS | BIOHAVEN PHARM HOLDING CO LTD (US) | 2023-11-29 | — | — | EP | disclosed |
| US-11827663-B2 | Use of UAP inhibitors to inhibit flux through the hexosamine biosynthetic pathway | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-28 | — | — | US | disclosed |
| US-11746114-B2 | Thermally sensitive protecting groups for cysteine for peptide cyclization and selective disulfide bond formation | UNIVERSITY OF WINDSOR (CA) | 2023-09-05 | — | — | US | disclosed |
| WO-2023010200-A1 | THERAPEUTIC COORDINATION POLYMERS CONTAINING PHARMACEUTICALS FOR DRUG RELEASE APPLICATIONS | UNIVERSITY OF WINDSOR (CA) | 2023-02-09 | — | — | WO | disclosed |
| US-11560387-B2 | Thermally sensitive protecting groups for cysteine, and manufacture and use thereof | UNIVERSITY OF WINDSOR (CA) | 2023-01-24 | — | — | US | disclosed |
| US-11377558-B2 | Stretchable, degradable and self-healing polymers through a combination of imine bonds and metal coordination | UNIVERSITY OF WINDSOR (CA) | 2022-07-05 | — | — | US | disclosed |
| WO-2006053109-A1 | HETEROARYL COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20050282802-A1 | Disalt inhibitors of IL-12 production | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| WO-2005112938-A2 | DISALT INHIBITORS OF IL-12 PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |